Literature DB >> 7875181

Interindividual variability of coumarin 7-hydroxylation in a Turkish population.

M Iscan1, H Rostami, M Iscan1, T Güray, O Pelkonen, A Rautio.   

Abstract

One hundred healthy Turkish volunteers (70 male, 30 female) aged from 19 to 56 years were given 5 mg coumarin p.o. after an overnight fast. Urine samples were collected before and 2, 4 and 8 h after drug administration. The extent and rate of formation of 7-OH-coumarin (7OHC) was determined by the urinary excretion of the metabolite as measured with the fluorometric method. On average, 80% of 7OHC formed was excreted in 2 h. The total amount of 7OHC formed was 59.8% (21.5%) (mean and SD, n = 100, range 17-100%) of the given dose. The percentage of 7OHC excreted during the first 2 h compared with the 7OHC excretion at 8 h was a constant and stable individual characteristic for the rate of the formation of 7OHC ('2 h coumarin test'). Although four individuals had relatively slow coumarin test values (34-40%), no clear-cut polymorphism in the rate of 7OHC formation was found. However, 7OHC formation was lower in males and in cigarette smokers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7875181     DOI: 10.1007/bf00191161

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine.

Authors:  S Cholerton; M E Idle; A Vas; F J Gonzalez; J R Idle
Journal:  J Chromatogr       Date:  1992-03-27

2.  Mouse hepatic cytochrome P-450 isozyme induction by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene, pyrazole, and phenobarbital.

Authors:  H Raunio; A Kojo; R Juvonen; P Honkakoski; P Järvinen; M A Lang; K Vähäkangas; H V Gelboin; S S Park; O Pelkonen
Journal:  Biochem Pharmacol       Date:  1988-11-01       Impact factor: 5.858

3.  Mouse liver P450Coh: genetic regulation of the pyrazole-inducible enzyme and comparison with other P450 isoenzymes.

Authors:  M A Lang; R Juvonen; P Järvinen; P Honkakoski; H Raunio
Journal:  Arch Biochem Biophys       Date:  1989-05-15       Impact factor: 4.013

4.  Analysis of coumarin and its urinary metabolites by high-performance liquid chromatography.

Authors:  E Moran; R O'Kennedy; R D Thornes
Journal:  J Chromatogr       Date:  1987-04-24

5.  Genetic variation between mice in their metabolism of coumarin and its derivatives.

Authors:  I E Lush; K M Andrews
Journal:  Genet Res       Date:  1978-04       Impact factor: 1.588

Review 6.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

7.  Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity.

Authors:  J S Miles; A W McLaren; L M Forrester; M J Glancey; M A Lang; C R Wolf
Journal:  Biochem J       Date:  1990-04-15       Impact factor: 3.857

8.  First-pass effect of coumarin in man.

Authors:  W A Ritschel; M E Brady; H S Tan
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-03

9.  Genetic variation in coumarin hydroxylase activity in the mouse (Mus musculus).

Authors:  A W Wood; A H Conney
Journal:  Science       Date:  1974-08-16       Impact factor: 47.728

Review 10.  The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature.

Authors:  D W Nebert; D R Nelson; M J Coon; R W Estabrook; R Feyereisen; Y Fujii-Kuriyama; F J Gonzalez; F P Guengerich; I C Gunsalus; E F Johnson
Journal:  DNA Cell Biol       Date:  1991 Jan-Feb       Impact factor: 3.311

View more
  9 in total

1.  Effects of nicotine on cytochrome P450 2A6 and 2E1 activities.

Authors:  Janne Hukkanen; Peyton Jacob Iii; Margaret Peng; Delia Dempsey; Neal L Benowitz
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

2.  A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.

Authors:  André Dallmann; Ibrahim Ince; Katrin Coboeken; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

Review 3.  [Preoperative abstinence from smoking. An outdated dogma in anaesthesia?].

Authors:  B Zwissler; A Reither
Journal:  Anaesthesist       Date:  2005-06       Impact factor: 1.041

4.  Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens.

Authors:  Toufigh Gordi; Dinh Xuan Huong; Trinh Ngoc Hai; Nguyen Thi Nieu; Michael Ashton
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

5.  Artemisinin and CYP2A6 activity in healthy subjects.

Authors:  Sara Asimus; Trinh Ngoc Hai; Nguyen Van Huong; Michael Ashton
Journal:  Eur J Clin Pharmacol       Date:  2007-12-07       Impact factor: 2.953

6.  Inter-individual Variability of Coumarin 7-hydroxylation (CYP2A6 activity) in an Iranian Population.

Authors:  Mohammad Hassanzadeh Khayyat; Nasser Vahdati Mashhadian; Saeed Eghbal; Navid Jalali
Journal:  Iran J Basic Med Sci       Date:  2013-04       Impact factor: 2.699

7.  New Metabolites of Coumarin Detected in Human Urine Using Ultra Performance Liquid Chromatography/Quadrupole-Time-of-Flight Tandem Mass Spectrometry.

Authors:  Letícia Paula Leonart; João Cleverson Gasparetto; Flávia Lada Degaut Pontes; Letícia Bonancio Cerqueira; Thais Martins Guimarães de Francisco; Roberto Pontarolo
Journal:  Molecules       Date:  2017-11-22       Impact factor: 4.411

8.  Genetics of tobacco use.

Authors:  Nancy Nairi Maserejian; Athanasios I Zavras
Journal:  Tob Induc Dis       Date:  2004-06-15       Impact factor: 2.600

9.  Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population.

Authors:  Nada Ezzeldin; Dalia El-Lebedy; Amira Darwish; Ahmed El Bastawisy; Shereen Hamdy Abd Elaziz; Mirhane Mohamed Hassan; Amal Saad-Hussein
Journal:  BMC Cancer       Date:  2018-05-03       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.